title: A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma.
abstract: BACKGROUND
  Combination chemotherapy consisting of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin (MACOP-B) has been frequently used for the treatment of non-Hodgkin's lymphoma. This randomized study was undertaken to assess the efficacy and toxicity of this regimen when either doxorubicin or epirubicin was used as the anthracycline drug.
  
  
  METHODS
  Between April 1989 and December 1993, 211 previously untreated patients with intermediate grade and high grade non-Hodgkin's lymphoma were randomized to receive either doxorubicin (n=106) or epirubicin (n=105) with the MACOP-B regimen. These patients were followed through December 1996. Numerous clinical features predictive of response and survival were analyzed. Cardiac and noncardiac toxicity in the two treatment arms were compared.
  
  
  RESULTS
  The median age of the patients was 48 years. Complete remission was experienced by 122 patients (58.3%); 62 patients (58.5%) achieved complete remission in the doxorubicin arm and 60 (58.1%) in the epirubicin arm. Response rates, time to treatment failure, relapse data, and overall survival were comparable between the two arms. Morbidity due to mucositis, vomiting, peripheral neuropathy, and cardiotoxicity were also comparable. The overall mortality was 10%. Mortality due to neutropenic sepsis was considerably higher among patients who received epirubicin (10 patients) than among those who received doxorubicin (5 patients). Cardiac evaluation revealed no difference in toxicity between the two arms.
  
  
  CONCLUSIONS
  Epirubicin was as effective as doxorubicin in terms of patients' responses to therapy. There was no difference in cardiotoxicity between the two treatment arms. However, in this study, the mortality due to neutropenic sepsis was significantly higher among patients treated with epirubicin.
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Parel, India.
authors.forename: R
authors.initials: R
authors.lastname: Nair
authors.forename: G
authors.initials: G
authors.lastname: Ramakrishnan
authors.forename: N N
authors.initials: NN
authors.lastname: Nair
authors.forename: T K
authors.initials: TK
authors.lastname: Saikia
authors.forename: P M
authors.initials: PM
authors.lastname: Parikh
authors.forename: S R
authors.initials: SR
authors.lastname: Joshi
authors.forename: C S
authors.initials: CS
authors.lastname: Soman
authors.forename: M
authors.initials: M
authors.lastname: Mukhadan
authors.forename: K T
authors.initials: KT
authors.lastname: Dinshaw
authors.forename: S H
authors.initials: SH
authors.lastname: Advani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin